NBIX vs ZBH
Neurocrine Biosciences vs Zimmer Biomet — AI-powered side-by-side comparison
NBIX
Neurocrine Biosciences
63
Buy
VS
| Metric | NBIX | ZBH |
|---|
| AI Score |
63
|
70
|
| Price |
$163.26
|
$96.61
|
| P/E Ratio |
23.18×
|
23.38×
|
| ROE |
14.7%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
98.0%
|
69.9%
|
| Debt / Equity |
0.11×
|
0.59×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
37.5
|
58.9
|
| Beta |
0.386
|
0.468
|
| Expected Upside |
—
|
+1.2%
|
AI Committee View
Current Innellis committee reasoning for NBIX versus ZBH.
ZBH leads by 7 points.
ZBH scores 70/100 (Buy) versus NBIX at 63/100 (Buy).
NBIX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 21.1% shows genuine earnings power backing the valuation — Value
- Revenue growing 34.4% YoY -- genuine top-line momentum — Growth
- EPS growing 101.3% YoY — Growth
Bear Case
- Price-to-book of 4.3x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 16.0% signals elevated volatility — Risk
ZBH Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Risk/reward is unfavorable: 11.2% downside vs 1.2% upside.